Skip to content

Evaluation of Cardiovascular Risks Among the Participants of the ESC Congress 2025

Cross-Sectional Assessment of Cardiovascular Risk Among ESC Congress 2025 Participants

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07613229
Acronym
ESC-CVRISK2025
Enrollment
1366
Registered
2026-05-29
Start date
2025-08-29
Completion date
2025-09-01
Last updated
2026-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk

Brief summary

The European Society of Cardiology (ESC) is dedicated to promoting cardiovascular (CV) health and minimizing the occurrence of cardiovascular diseases throughout Europe. As a founding member of the European Alliance for Cardiovascular Health (EACH), the ESC is advocating for European and National Cardiovascular Health Plans which would include a cardiovascular and diabetes health check as part of a screening process for citizens. In line with this call for public health diagnosis of CV health, the ESC is committed to raising awareness on the need for actions and proposes to offer complimentary tests to delegates at ESC Congress 2025 in Madrid.

Interventions

BEHAVIORALQuestionnaire and Physical Exam

Questionnaire about demographics information, medical history and current CV medication.

BIOLOGICALblood draw

Blood draw

PROCEDUREauscultation

Auscultation procedure to measure the presence or absence of cardiac murmur and normal or abnormal heart sounds

Sponsors

European Society of Cardiology
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* All healthcare professionals (doctors, nurses, etc.) attending the ESC Congress 2025 from August 29th to September 1st * Subjects who declare that they are able to understand and give IC in English

Exclusion criteria

* Subjects not willing to provide his/her consent to participate in the study. * Subjects who are not suitable candidates for blood extraction.

Design outcomes

Primary

MeasureTime frame
Systemic Coronary Risk Evaluation 2 (SCORE2) algorithm in patients without established CVD (primary prevention).At baseline
Second Manifestations or Arterial Disease (SMART) algorithm in patients with established CVD (secondary prevention)At baseline

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026